TACR1 and neoplasm: Utilizing the TACR1 antagonist aprepitant, a medication employed to mitigate nausea and vomiting induced by chemotherapy and surgery, has demonstrated efficacy in inhibiting the growth and metastasis of various murine breast cancer cell types by targeting this neuro-tumor signaling pathway.